Clinical Trials

75 enrolled

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT00923507 2026-06-05

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

1,000 enrolled

Leukemia, Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01087333 2026-06-05

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

DermatologicLymphoidOther hematologic neoplasm

1,263 enrolled

Hemolytic-Uremic Syndrome, Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02682667 2026-06-05

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

LymphoidOther hematologic neoplasmOther neoplasmPlasma cellThoracic

500 enrolled

Carcinoma, Non-Small-Cell Lung, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precancerous Conditions, Leukemia-Lymphoma, Adult T-Cell

NCT03190928 2026-06-05

Clonal Evolution in Follicular Lymphoma

200 enrolled

Lymphoma, Follicular

NCT03223610 2026-06-05

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Phase 1/2 Recruiting

155 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03258567 2026-06-05

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

40 enrolled

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT03922724 2026-06-05

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

330 enrolled

Autoimmune Diseases, Immune System Diseases, Lymphoproliferative Disorders, Opportunistic Infections, Lymphoma, T-Cell, Peripheral

NCT04840602 2026-06-05

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

92 enrolled

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05621291 2026-06-05

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

Phase NA Recruiting

60 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05724121 2026-06-05

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

135 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Arrhythmias, Cardiac, Atrial Fibrillation, Leukemia, Lymphocytic, Chronic, B-Cell, Death, Sudden, Cardiac, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06860594 2026-06-05

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Phase 1 Suspended

30 enrolled

CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT06904066 2026-06-05

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Phase 1 Recruiting

86 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07328503 2026-06-05

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

20 enrolled

Phase 2 Not yet recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07524530 2026-06-05

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

98 enrolled

Phase 1 Not yet recruiting

Leukemia, Lymphoma, Hematologic Neoplasms

NCT07572136 2026-06-05

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

57 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00039676 2026-06-04

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

Active not recruiting

1,836 enrolled

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00923442 2026-06-04

Biology Studies of Hematologic Cancers

Enrolling by invitation

550 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07428707 2026-06-04

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

Phase EARLY_PHASE1 Recruiting

30 enrolled

Phase 3 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

669 enrolled 14 charts

Phase 3 Active not recruiting

Burkitt Lymphoma

NCT02112916 2026-06-03

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

847 enrolled 19 charts

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 1 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03739814 2026-06-03

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

84 enrolled

Burkitt Lymphoma

NCT04002947 2026-06-03

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

132 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Phase 3 Recruiting

1,875 enrolled

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06124157 2026-06-03

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

222 enrolled

Burkitt Lymphoma

NCT06317662 2026-06-03

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT07003295 2026-06-03

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

20 enrolled

Lymphoma, Mantle-Cell

NCT02883049 2026-06-02

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Phase 3 Completed

5,949 enrolled 28 charts

Burkitt Lymphoma

NCT03213704 2026-06-02

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

9 enrolled 12 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT04439292 2026-06-02

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

LymphoidOther hematologic neoplasmPlasma cell

44 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04458922 2026-06-02

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

27 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Follicular, Sarcoma, Clear Cell

NCT04742387 2026-06-02

Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis

Active not recruiting

40 enrolled

LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Bone Diseases, Metabolic, Sarcoma, Kaposi, Lymphoma, Primary Effusion

NCT05907759 2026-06-02

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

28 enrolled

LymphoidSarcoma

Multi-centric Castleman's Disease, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, Primary Effusion

NCT00032513 2026-06-01

Genetic Studies of Chronic Active Epstein-Barr Disease

300 enrolled

GenitourinaryLymphoidPlasma cell

Herpes Simplex, Infectious Mononucleosis, Lymphoproliferative Disorders, Virus Diseases, Epstein-Barr Virus Infections

NCT00352924 2026-06-01

Agriculture Health Study

Active not recruiting

89,655 enrolled

Lymphoma, Multiple Myeloma, Neoplasms, Prostatic Neoplasms

NCT00900198 2026-06-01

Collection of Tissue Samples for Cancer Research

LymphoidMyeloidPlasma cell

5,000 enrolled

Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms

NCT01087294 2026-06-01

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Phase 1 Completed

85 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

NCT01563874 2026-06-01

Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins

Completed

130 enrolled

CNSLymphoidOther hematologic neoplasmSarcoma

Lymphoma

NCT02390752 2026-06-01

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

Phase 1 Recruiting

54 enrolled

Sarcoma, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

1,377 enrolled 10 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT03210714 2026-06-01

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)